# A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder

> **NCT00576732** · PHASE4 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 96 (actual)

## Conditions studied

- Autistic Disorder
- Autism

## Interventions

- **DRUG:** Placebo
- **DRUG:** Risperidone high dose
- **DRUG:** Risperidone low dose

## Key facts

- **NCT ID:** NCT00576732
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-09
- **Final completion:** 2010-03
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2014-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00576732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00576732, "A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00576732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*